Good
Mostly Aligned
Patient Risk:
Moderate
Summary
Most statements align with the provided label excerpts regarding indication, adjunct use, and mechanism (COMT inhibition). Minor deductions for partially supported mechanistic details and omission of key labeled safety/administration specifics (dose timing/food restrictions, contraindications, and hepatic impairment guidance).
Category Scores
Accurate Statements
Ongentys contains opicapone.
Active ingredient: opicapone (implied by label stating Opicapone is mechanism of action inhibitor; label identifies ONGENTYS as opicapone-based product).
Ongentys is designed to reduce “off” time in people with Parkinson’s disease who take levodopa.
Indicated as adjunctive treatment to levodopa/carbidopa in PD experiencing “off” episodes (1); Clinical studies show reduction in mean absolute OFF-time (14).
Opicapone is used as an add-on to levodopa therapy.
Indications and Usage: adjunctive treatment to levodopa/carbidopa (1).
Ongentys is used as an adjunct (add-on) to levodopa therapy in Parkinson’s disease.
Indications and Usage (1).
Ongentys is used for people experiencing wearing-off or increased off time despite taking levodopa/carbidopa (or another standard levodopa-based regimen).
Indicated for PD experiencing “off” episodes in patients on levodopa/carbidopa (1).
Ongentys is not intended to replace levodopa.
Adjunctive treatment to levodopa/carbidopa (1).
Opicapone works by changing how long levodopa stays active in the body.
Label: Peak and overall levodopa exposure increased; COMT inhibition maintains >65% over 24 hours (12.3).
Opicapone blocks catechol-O-methyltransferase (COMT).
Mechanism of action: selective and reversible inhibitor of COMT (12.1); Pharmacodynamics: inhibition of COMT activity (12.3).
COMT inhibition extends levodopa’s effect after a dose.
Once-daily dosing maintains inhibition of COMT activity over 24-hour dosing interval (12.3) and increases levodopa exposure (12.3), consistent with extended effect.
Opicapone can reduce periods when medications wear off and symptoms return (“off” episodes).
Indication for “off” episodes (1) and clinical studies reduce mean absolute OFF-time (14).
COMT inhibitors like opicapone are used to target reduced “off” time (when levodopa effects diminish).
Indication and clinical studies show treatment of “off” episodes/OFF-time (1, 14). (Specific class statement is not explicitly made, but opicapone’s use targets OFF-time in the label).
Common adverse effects associated with COMT inhibitors in this class can include dyskinesia.
Dyskinesia is described as a may/can occur potentiation and is the most common adverse reaction leading to discontinuation (5.4); most common adverse reactions include dyskinesia (6.1).
Other COMT inhibitors (including entacapone) share the core approach of slowing levodopa breakdown via COMT.
Label supports that opicapone is a COMT inhibitor (12.1) and COMT inhibition affects levodopa exposure (12.3); it does not explicitly mention entacapone in provided excerpts, but the shared mechanism premise is consistent with the label’s COMT inhibition framing.
Unsupported Statements
COMT normally breaks down levodopa in the bloodstream and other tissues.
Provided label excerpts describe COMT inhibition and its effect on levodopa exposure, but do not explicitly state COMT’s physiological role as breaking down levodopa in bloodstream/other tissues.
Inhibiting COMT makes levodopa broken down more slowly.
Label excerpts support COMT inhibition and increased levodopa exposure, but do not explicitly phrase the mechanism as 'broken down more slowly'.
When COMT is inhibited, more of the levodopa dose becomes available to convert to dopamine in the brain.
Label excerpts provided do not explicitly state dopamine conversion or 'more becomes available' wording.
Ongentys is taken on a dosing schedule alongside levodopa-based medication.
Adjunctive use is supported, but the specific scheduling/dosing schedule phrasing is not explicitly provided in the excerpt beyond 'once daily at bedtime' and food restrictions.
Contradictions
Important Omissions
Dose and administration specifics: 50 mg orally once daily at bedtime; no food 1 hour before and at least 1 hour after intake.
Importance:
High
Contraindications: concomitant use of non-selective MAO inhibitors; pheochromocytoma/paraganglioma/catecholamine-secreting neoplasms.
Importance:
High
Key warnings/precautions beyond dyskinesia: falling asleep/somnolence, hypotension/syncope, hallucinations/psychosis, impulse control disorders, and withdrawal-emergent hyperpyrexia/confusion.
Importance:
Moderate
Drug interaction monitoring statement for COMT-metabolized drugs and MAO inhibitors risk/arrhythmias/BP changes.
Importance:
High
Hepatic impairment guidance: avoid in severe (Child-Pugh C); recommended 25 mg once daily at bedtime in moderate (Child-Pugh B); no adjustment in mild (Child-Pugh A).
Importance:
Moderate
Monitoring and discontinuation guidance on missed dose/adjusting other dopaminergic therapy when stopping.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While the core efficacy/adjunct mechanism claims are broadly aligned, the response omits several high-relevance label elements (contraindications, interaction warnings, and detailed administration/food timing), which are important for safe prescribing per the provided excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Missing key labeled safety, contraindications, drug interaction monitoring, and exact administration/food timing details; some mechanistic statements are not explicitly supported by the provided excerpts.
Suggested Improvement
Add label-supported contraindications (non-selective MAO inhibitors; pheochromocytoma/paraganglioma/catecholamine-secreting neoplasms), key warnings/precautions (somnolence/falling asleep, hypotension/syncope, hallucinations/psychosis, impulse control, withdrawal-emergent hyperpyrexia/confusion), interaction monitoring language (COMT-metabolized drugs; MAO inhibitors), and exact dosing/food instructions (50 mg qhs; no food 1 hour before and at least 1 hour after; plus hepatic impairment dosing/avoidance guidance).